BiotechTube

Fx-1006A + Placebo

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Familial Amyloid Polyneuropathy

Conditions

Familial Amyloid Polyneuropathy

Trial Timeline

Jan 1, 2007 → May 1, 2009

NCT ID
NCT00409175

About Fx-1006A + Placebo

Fx-1006A + Placebo is a phase 2/3 stage product being developed by Pfizer for Familial Amyloid Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00409175. Target conditions include Familial Amyloid Polyneuropathy.

What happened to similar drugs?

1 of 20 similar drugs in Familial Amyloid Polyneuropathy were approved

Approved (1) Terminated (3) Active (17)
🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
🔄rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
🔄Rosuvastatin + PlaceboAstraZenecaPhase 3
🔄Rosuvastatin 20mgAstraZenecaPhase 3
🔄AZD0780 + PlaceboAstraZenecaPhase 3
🔄Anacetrapib + Placebo for anacetrapibMerckPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00409175Phase 2/3Completed

Competing Products

20 competing products in Familial Amyloid Polyneuropathy

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
AZD0780 + PlaceboAstraZenecaPhase 3
44
Anacetrapib + Placebo for anacetrapibMerckPhase 3
40
Statins and EzetimibeMerckPre-clinical
22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
32
MK-0524A + MK-0524AMerckPhase 1
21
Enlicitide Decanoate + PlaceboMerckPhase 2/3
45
Inclisiran + PlaceboNovartisPhase 3
40
DFV890NovartisPhase 2
35
CanakinumabNovartisPhase 2
35
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
LCQ908 + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
40